RecruitingEarly Phase 1NCT04480645
CivaDerm(TM) Surface Therapy Pilot Study
Sponsor
CivaTech Oncology
Enrollment
10 participants
Start Date
May 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma patients by providing conformal radiation therapy to the surface of the skin.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- subject signed informed consent
- Confirmed superficial or nodular basal cell or squamous cell carcinoma
- Biopsy proven on chest, stomach, back, arms, legs, feet (trunk and extremities)
- \>5 mm of residual tumor
- tumors \< 3 cm
- Capable of complying with Patient Release Instructions
Exclusion Criteria3
- Is unable or unwilling to comply with the protocol requirements
- Pregnant or breast feeding
- Metastases
Interventions
DEVICECivaDerm
radioactive bandage
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04480645
Related Trials
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
NCT0434943628 locations
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
NCT071822401 location
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
NCT066244753 locations
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT072850441 location
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
NCT058590747 locations